Metabolic syndrome and associated chronic kidney diseases: Nutritional interventions

Reviews in Endocrine and Metabolic Disorders

Volumn 14, Issue 3, 2013, Pages 273-286

  Anil Kumar, P ^a   Swathi Chitra, P ^b   Bhanuprakash Reddy, G ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b INDIRA GANDHI NATIONAL OPEN UNIVERSITY   (India)

Author keywords

Chronic kidney disease; End stage kidney disease; Hyperglycemia; Metabolic syndrome; Obesity; Renal complications

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ANGIOTENSIN II; C REACTIVE PROTEIN; GROWTH FACTOR; INSULIN; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN; POLYOL; PROTEIN KINASE C; TRIACYLGLYCEROL; UNSATURATED FATTY ACID;

ABDOMINAL OBESITY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY MALFORMATION; LIFESTYLE MODIFICATION; LIPOTOXICITY; METABOLIC SYNDROME X; NEPHRITIS; NUTRITIONAL ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROPHYLAXIS; PROTEINURIA; RISK FACTOR; SODIUM RESTRICTION; TREATMENT OUTCOME;

HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC SYNDROME X; OBESITY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84885618744     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-013-9268-2     Document Type: Article

References (109)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
2. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2011;34:216-9.
3. Kylin E. Studien ueber das Hypertonie-Hyperglyka "mie- Hyperurika" miesyndrom. Zbl Innere Med. 1923;44:105-27.
4. Vague J. La differenciation sexuelle, facteur determinant des formes de l'obesité. Presse Med. 1947;53:339-40.
5. Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia. 1965;1:137.
6. Hanefeld M, Leonhardt W. The metabolic syndrome [Das metabolische syndrom]. Dtsch Gesundheitsw. 1981;36:545-51.
7. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1998;37:1595-607.
8. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514-20.
9. Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715-22.
10. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
11. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-3.
12. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia;hyperapolipoprteinB; small dense LDL) in men? Circulation. 2000;102:179-84.
13. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-97.
14. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237-52.
15. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829-34.
16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469-80.
17. Grundy SM, Cleeman JI, Daniels SR, American Heart Association; National Heart, Lung, and Blood Institute, et al. Circulation. 2005;112:2735-52.
18. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
19. Cameron AJ, Magliano DJ, Zimmet PZ, et al. The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract. 2007;77:471-8.
20. Doupis J, Dimosthenopoulos C, Diamanti K, et al. Metabolic syndrome and Mediterranean dietary pattern in a sample of young, male, Greek navy recruits. Nutr Metab Cardiovasc Dis. 2009;19:e7-8.
21. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769-78.
22. Nitta K. Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular disease. Cardiol Res Pract. 2011;2011:963517.
23. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003;26:861-7.
24. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-8.
25. Lin WY, Liu CS, Li TC, et al. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study. Ann Rheum Dis. 2008;67:432-3.
26. Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013;22:198-203.
27. Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: the hypertension detection and follow-up program. Am J Kidney Dis. 2005;46:587-94.
28. Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of nondiabetic chronic kidney disease: a retrospective cohort study. Nephron Clin Pract. 2009;113:c16-23.
29. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005;46:871-80.
30. Chadban SJ, Briganti EM, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003;14(7 Suppl 2):S131-8.
31. Stevens PE, O'Donoghue DJ, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72(1):92-9.
32. K/DOQI. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
33. van der Velde M, Bakker SJ, de Jong PE, Gansevoort RT. Influence of age and measure of eGFR on the association between renal function and cardiovascular events. Clin J Am Soc Nephrol. 2010;5:2053-9.
34. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134-40.
35. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephritic syndrome: a complication of massive obesity. Ann Intern Med. 1974;81:440-7.
36. Klausen KP, Parving HH, Scharling H, Jensen JS. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol (Oxf). 2009;71:40-5.
37. Pinto-Sietsma SJ, Navis G, Janssen WM, et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003;41:733-41.
38. Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000;58:2111-8.
39. Praga M. Obesity - a neglected culprit in renal disease. Nephrol Dial Transplant. 2002;17:1157-9.
40. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498-509.
41. Deji N, Kume S, Araki S, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Ren Physiol. 2009;296:F118-26.
42. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167-74.
43. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952-8.
44. Thomas G, Sehgal AR, Kashyap SR, et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364-73.
45. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:550-62.
46. Espinoza R, Gracida C, Cancino J, et al. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc. 2006;38:888-9.
47. Hsu CY, McCulloch CE, Iribarren C, Darbinian J. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21-8.
48. Ejerblad E, Fored M, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk of chronic renal failure. J Am Soc Nephrol. 2006;17:1695-702.
49. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211-7.
50. Abitbol CL, Rodriguez MM. Obesity-related nephropathy in children. Pediatr Health. 2009;3:141-53.
51. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17:2985-91.
52. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4:43-55.
53. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15:2792-800.
54. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-54.
55. Ramkumar N, Cheung AK, Pappas LM, Roberts WL, Beddhu S. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr. 2004;14:201-7.
56. Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, Ma X, et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006;147:44-50.
57. Camici M, Galetta F, Abraham N, Carpi A. Obesity-related glomerulopathy and podocyte injury: a mini review. Front Biosci (Elite Ed). 2012;4:1058-70.
58. Kirschenbaum MA, Pai R, Roh DD, Kamanna VS. Role of atherogenic lipoproteins in cytokine-mediated renovascular injury. Miner Electrolyte Metab. 1996;22:47-50.
59. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56.
60. Yano Y, Hoshide S, Ishikawa J, et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertens (Greenwich). 2007;9:775-82.
61. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599-606.
62. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645-56.
63. Ma K, Cabrero A, Saha PK, et al. Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem. 2002;277:34658-61.
64. Ohashi K, Iwatani H, Kihara S, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin knockout mice. Arterioscler Thromb Vasc Biol. 2007;27:1910-7.
65. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009;76:145-8.
66. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999;56:860-72.
67. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006;151:175-83.
68. Menzaghi C, Salvemini L, Fini G, et al. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One. 2012;7:e38414.
69. Nehus EJ. Correlates of resistin in children with chronic kidney disease: the CKiD Cohort. Electronic Thesis. University of Cincinnati, 2011. https://etd.ohiolink.edu/.
70. D'Elia JA, Roshan B, Maski M, Weinrauch LA. Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney. Int J Nephrol Renov Dis. 2009;2:39-49.
71. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15:2775-91.
72. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 2004;24:46-53.
73. Nishida Y, Yorioka N, Oda H, Yamakido M. Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis. 1997;29:919-30.
74. Anil Kumar P, Bhanuprakash Reddy G. Focus on molecules: aldose reductase. Exp Eye Res. 2007;85:739-40.
75. Uribarri J, Tuttle K. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol. 2006;1:1293-9.
76. Schwedler SB, Metzger T, Schinzel R, et al. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002;62:301-10.
77. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerularsclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994;91:11704-8.
78. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123-37.
79. Isaka Y, Fujiwara Y, Ueda N, et al. Glomerulosclerosis induced in vivo transfection of transforming growth factor beta or platelet derived growth factor gene into rat kidney. J Clin Invest. 1992;92:2597-601.
80. Langham RG, Kelly DJ, Gow RM, et al. Transforming growth factor-β in human diabetic nephropathy, effects of ACE inhibition. Diabetes Care. 2006;29:2670-4.
81. Sahib MN, Abdulameer SA, Aziz NA, Hassan Y. Pathogenesis of diabetic kidney disease: review of cellular aspects of renal lesions. Afr J Pharm Pharmacol. 2009;3:507-14.
82. Kumar PA, Brosius 3rd FC, Menon RK. The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy. Curr Diabetes Rev. 2011;7:50-5.
83. Kumar PA, Kotlyarevska K, Dejkhmaron P, et al. Growth hormone (GH)-dependent expression of a natural antisense transcript induces zinc finger E-box-binding homeobox 2 (ZEB2) in the glomerular podocyte: a novel action of gh with implications for the pathogenesis of diabetic nephropathy. J Biol Chem. 2010;285:31148-56.
84. Gnudi L, Viberti G, Raij L, et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension. 2003;42:19-24.
85. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome-the optimal diet. Br J Nutr. 2000;83(Supp 1):S143-8.
86. Andersen CJ, Fernandez ML. Dietary strategies to reduce metabolic syndrome. Rev Endocr Metab Disord. 2013 Aug 13. PMID23943309 [Epub ahead of print].
87. Lakka TA, Laaksonen DE. Physical activity in prevention and treatment of the metabolic syndrome. Appl Physiol Nutr Metab. 2007;3276-88.
88. Healy GN, Wijndaele K, Dunstan DW, et al. Objectively measured sedentary time, physical activity, and metabolic risk: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Diabetes Care. 2008;31:369-71.
89. Ludwig DS. The glycemic index physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA. 2002;287:2414-23.
90. Babio N, Balanza R, Basulto J, Bulló M, Salas-Salvadó J. Dietary fibre: influence on body weight, glycemic control and plasma cholesterol profile. Nutr Hosp. 2010;25:327-40.
91. Aleixandre A, Miguel M. Dietary fiber in the prevention and treatment of metabolic syndrome: a review. Crit Rev Food Sci Nutr. 2008;48:905-12.
92. Gillingham LG, Harris-Janz S, Jones PJ. Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids. 2011;46:209-28.
93. Carpentier YA, Portois L, Malaisse WJ. Rapid enrichment of cell phospholipids in long-chain polyunsaturated ω-3 fatty acids after a bolus intravenous injection of a medium-chain triacylglycerol: fish oil emulsion in humans. J Parenter Enter Nutr. 2012;36:671-6.
94. Chen J, Gu D, Huang J, Rao DC, et al. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet. 2009;373:829-35.
95. Shimamoto K, Hirata A, Fukuoka M, Higashiura K, Miyazaki Y, Shiiki M, et al. Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension. 1994;23:129-33.
96. Galletti F, Strazzullo P, Ferrara I, Rivellese AA, Gatto S, Mancini M. Salt sensitivity of essential hypertensive patients is related to insulin resistance. J Hypertens. 1997;15:1485-91.
97. Kaysen GA, Rathore V. Derangements of protein metabolism in chronic renal failure. Blood Purif. 1996;14(5):373-81.
98. Slee AD. Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab. 2012;9:36.
99. Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86:899-906.
100. Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol. 2006;48:677-85.
101. Kasajima H, Yamagishi S, Sugai S, Yagihashi N, Yagihashi S. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch. 2001;439:46-54.
102. Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR, et al. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes. 1989;38:1258-70.
103. Robison Jr WG, Tillis TN, Laver N, Kinoshita JH. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp Eye Res. 1990;50:355-66.
104. Kassab JP, Guillot R, Andre J, Claperon N, Bellon G, Feldmann G, et al. Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional and ultrastructural studies. Biochem Pharmacol. 1994;48:1003-8.
105. Reeves WB, Rawal BB, Abdel-Rahman EM, Awad AS. Therapeutic modalities in diabetic nephropathy: future approaches. Open J Nephrol. 2012;2:5-18.
106. Saraswat M, Muthenna P, Suryanarayana P, Petrash JM, Reddy GB. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac J Clin Nutr. 2008;17:558-65.
107. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8:337-46.
108. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596-601.
109. Saraswat M, Reddy PY, Muthenna P, Reddy GB. Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications. Br J Nutr. 2009;101:1714-21.